Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Wins Ruling On Mircera Importation; Court to Hear Injunction Appeal

Executive Summary

Although it may not make much difference for its follow-on biologic Mircera (epoetin beta), Roche has won a battle with Amgen that could affirm a layer of intellectual property protection for all follow-on biologics in the U.S

You may also be interested in...



AbbVie’s Battle Over Alvotech’s Humira Biosimilar Moves To New Ground With ITC Investigation

International Trade Commission launches investigation of adalimumab manufacturing processes in response to AbbVie complaint of misappropriation of trade secrets. District court dismissed trade secret suit on grounds it lacked jurisdiction. Trial in infringement suit is set for August.

AbbVie’s Battle Over Alvotech’s Biosimilar Humira Moves To New Ground With ITC Investigation

International Trade Commission launches investigation of adalimumab manufacturing processes in response to AbbVie complaint of misappropriation of trade secrets. District court dismissed trade secret suit on grounds it lacked jurisdiction. Trial in infringement suit is set for August.

Court May Ask Roche To Pay Amgen 22.5 Percent Mircera Marketing Royalty

Preliminary injunction bars launch of Roche’s Mircera; suggests terms to avoid a permanent injunction.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051076

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel